RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents – New England Journal of Medicine

Related: [Press release – not published yet] Pfizer-BioNTech vaccine 100% effective against Covid-19 in adolescents

Commentary on Twitter

The 12-15 year-olds mRNA vaccine randomized, placebo-controlled clinical trial is published @NEJM today [@BioNTech_Group/@Pfizer]https://t.co/7GlgC9xdd0
—100% efficacy (95% CI 75,100)
—1.8 X higher levels of neutralizing antibodies than 16-25 yr olds
—very good safety profile pic.twitter.com/hQzkpuA5Nu

— Eric Topol (@EricTopol) May 27, 2021